BioCentury
ARTICLE | Clinical News

Alfacell reports Phase III data

May 23, 2000 7:00 AM UTC

ACEL said that preliminary results of a 154-patient Phase III trial of its Onconase ribonuclease agent in patients with unresectable malignant mesothelioma showed a median survival time of 7.7 months ...